Latest From Amakem NV
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.
Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.
Biopharma start-ups raised $299 million and just over half were Series A rounds. Device companies brought in $134 million, while two diagnostics firms raised $10 million total. Ophthalmology was the most popular theracat for biopharma alliances. Just one acquisition involving a start-up took place.
- Therapeutic Areas
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Amakem NV
- Senior Management
Jack Elands, CEO
Dirk Leysen, CSO
Olivier Defert, Dir., External R&D
- Contact Info
Phone: (32) 11 286 982
Agoralaan Bldg. A Bis
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.